fig7

Figure 7. Schematic representation of targeted tumor therapy using nanoplatforms. (A) Schematic illustration of NIR-II-responsive AuPB@mPDA-DNase-mediated NETs degradation. By releasing DNase I to degrade NETs, this approach enhances the anticancer efficacy of immunotherapy and prevents liver metastasis; (B) GSH-responsive mP-NPs-DNase/PTX nanomaterials release PTX and DNase I, inhibiting tumor growth and distant metastasis; (C) Diagram showing cANP preparation and the use of cationic polymers to selectively bind NET-DNA, inhibiting cancer metastasis to the liver; (D) Diagram depicting cell membrane hybrid liposomes engineered through genetic modification for the specific elimination of NETs through CCDC25 targeting of NET-DNA and the action of DNase I. These figures are quoted with permission^[110-113]. NIR-II: second near-infrared; NET: neutrophils extracellular trap; GSH: glutathione; PTX: paclitaxel; cANP: the poly (aspartic acid)-based cationic nanoparticle; DNA: deoxyribonucleic acid; CCDC25: coiled-coil domain containing protein 25.